These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 33935654)

  • 1. Striatal Dopamine Transporter Function Is Facilitated by Converging Biology of α-Synuclein and Cholesterol.
    Threlfell S; Mohammadi AS; Ryan BJ; Connor-Robson N; Platt NJ; Anand R; Serres F; Sharp T; Bengoa-Vergniory N; Wade-Martins R; Ewing A; Cragg SJ; Brimblecombe KR
    Front Cell Neurosci; 2021; 15():658244. PubMed ID: 33935654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson's.
    Brimblecombe KR; Connor-Robson N; Bataille CJR; Roberts BM; Gracie C; O'Connor B; Te Water Naude R; Karthik G; Russell AJ; Wade-Martins R; Cragg SJ
    Eur J Neurosci; 2024 Mar; 59(6):1242-1259. PubMed ID: 37941514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striatal dopamine transmission is subtly modified in human A53Tα-synuclein overexpressing mice.
    Platt NJ; Gispert S; Auburger G; Cragg SJ
    PLoS One; 2012; 7(5):e36397. PubMed ID: 22570709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α-synuclein BAC transgenic mouse.
    Taylor TN; Potgieter D; Anwar S; Senior SL; Janezic S; Threlfell S; Ryan B; Parkkinen L; Deltheil T; Cioroch M; Livieratos A; Oliver PL; Jennings KA; Davies KE; Ansorge O; Bannerman DM; Cragg SJ; Wade-Martins R
    Neurobiol Dis; 2014 Feb; 62():193-207. PubMed ID: 24121116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice.
    Kurz A; Double KL; Lastres-Becker I; Tozzi A; Tantucci M; Bockhart V; Bonin M; García-Arencibia M; Nuber S; Schlaudraff F; Liss B; Fernández-Ruiz J; Gerlach M; Wüllner U; Lüddens H; Calabresi P; Auburger G; Gispert S
    PLoS One; 2010 Jul; 5(7):e11464. PubMed ID: 20628651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Redistribution of DAT/α-synuclein complexes visualized by "in situ" proximity ligation assay in transgenic mice modelling early Parkinson's disease.
    Bellucci A; Navarria L; Falarti E; Zaltieri M; Bono F; Collo G; Spillantini MG; Missale C; Spano P
    PLoS One; 2011; 6(12):e27959. PubMed ID: 22163275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Optically and Electrically Evoked Dopamine Release in Striatal Slices from Digenic Knock-in Mice with DAT-Driven Expression of Channelrhodopsin.
    O'Neill B; Patel JC; Rice ME
    ACS Chem Neurosci; 2017 Feb; 8(2):310-319. PubMed ID: 28177213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein.
    Senior SL; Ninkina N; Deacon R; Bannerman D; Buchman VL; Cragg SJ; Wade-Martins R
    Eur J Neurosci; 2008 Feb; 27(4):947-57. PubMed ID: 18333965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine Transporter/α-Synuclein Complexes Are Altered in the Post Mortem Caudate Putamen of Parkinson's Disease: An In Situ Proximity Ligation Assay Study.
    Longhena F; Faustini G; Missale C; Pizzi M; Bellucci A
    Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29848975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex and Age Differences in a Progressive Synucleinopathy Mouse Model.
    Lamontagne-Proulx J; Coulombe K; Morissette M; Rieux M; Calon F; Di Paolo T; Soulet D
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striatal dopamine neurotransmission is altered in age- and region-specific manner in a Parkinson's disease transgenic mouse.
    Medina-Luque J; Piechocinski P; Feyen P; Sgobio C; Herms J
    Sci Rep; 2024 Jan; 14(1):164. PubMed ID: 38167878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
    Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
    Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of motor performance, brain biochemistry and histology of two A30P α-synuclein transgenic mouse strains.
    Piltonen M; Savolainen M; Patrikainen S; Baekelandt V; Myöhänen TT; Männistö PT
    Neuroscience; 2013 Feb; 231():157-68. PubMed ID: 23219665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms underlying altered striatal synaptic plasticity in old A53T-α synuclein overexpressing mice.
    Tozzi A; Costa C; Siliquini S; Tantucci M; Picconi B; Kurz A; Gispert S; Auburger G; Calabresi P
    Neurobiol Aging; 2012 Aug; 33(8):1792-9. PubMed ID: 21684039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of the PDZ domain-binding motif of the dopamine transporter uniquely alters nanoscale distribution, dopamine homeostasis, and reward motivation.
    Sørensen G; Rickhag M; Leo D; Lycas MD; Ridderstrøm PH; Weikop P; Lilja JH; Rifes P; Herborg F; Woldbye D; Wörtwein G; Gainetdinov RR; Fink-Jensen A; Gether U
    J Biol Chem; 2021 Dec; 297(6):101361. PubMed ID: 34756883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deficits in basal and evoked striatal dopamine release following alpha-synuclein preformed fibril injection: An in vivo microdialysis study.
    Centner A; Del Priore I; Chambers N; Cohen SR; Terry ML; Coyle M; Glinski J; Stoll AC; Patterson JR; Kemp CJ; Miller KM; Kubik M; Kuhn N; Luk KC; Sortwell CE; Bishop C
    Eur J Neurosci; 2024 Apr; 59(7):1585-1603. PubMed ID: 38356120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake.
    Castro-Hernández J; Afonso-Oramas D; Cruz-Muros I; Salas-Hernández J; Barroso-Chinea P; Moratalla R; Millan MJ; González-Hernández T
    Neurobiol Dis; 2015 Feb; 74():325-35. PubMed ID: 25511804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkin disrupts the alpha-synuclein/dopamine transporter interaction: consequences toward dopamine-induced toxicity.
    Moszczynska A; Saleh J; Zhang H; Vukusic B; Lee FJ; Liu F
    J Mol Neurosci; 2007; 32(3):217-27. PubMed ID: 17873367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress.
    Wersinger C; Prou D; Vernier P; Sidhu A
    FASEB J; 2003 Nov; 17(14):2151-3. PubMed ID: 12958153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study.
    Wilson H; Dervenoulas G; Pagano G; Koros C; Yousaf T; Picillo M; Polychronis S; Simitsi A; Giordano B; Chappell Z; Corcoran B; Stamelou M; Gunn RN; Pellecchia MT; Rabiner EA; Barone P; Stefanis L; Politis M
    Lancet Neurol; 2019 Aug; 18(8):748-759. PubMed ID: 31229470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.